|
US5716965A
(en)
*
|
1991-05-22 |
1998-02-10 |
Pfizer Inc. |
Substituted 3-aminoquinuclidines
|
|
RU2114848C1
(ru)
*
|
1991-06-20 |
1998-07-10 |
Пфайзер Инк. |
Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ ингибирования действия вещества р у млекопитающих
|
|
TW202432B
(cs)
*
|
1991-06-21 |
1993-03-21 |
Pfizer |
|
|
MY110227A
(en)
*
|
1991-08-12 |
1998-03-31 |
Ciba Geigy Ag |
1-acylpiperindine compounds.
|
|
EP0533280B2
(en)
*
|
1991-09-20 |
2004-12-01 |
Glaxo Group Limited |
Novel medical use for tachykinin antagonists
|
|
CA2324959C
(en)
*
|
1991-11-12 |
2002-11-12 |
Pfizer Limited |
Phthalimido compounds as intermediates for producing substance p receptor antagonists
|
|
DK0641328T3
(da)
*
|
1992-05-18 |
2002-05-21 |
Pfizer |
Broforbundne, azabicykliske derivater som substans P-antagonister
|
|
US6048859A
(en)
|
1992-06-29 |
2000-04-11 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
|
US5637699A
(en)
*
|
1992-06-29 |
1997-06-10 |
Merck & Co., Inc. |
Process for preparing morpholine tachykinin receptor antagonists
|
|
US5719147A
(en)
*
|
1992-06-29 |
1998-02-17 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
|
US5688804A
(en)
*
|
1992-08-04 |
1997-11-18 |
Pfizer Inc. |
3-Benzylamino-2-phenyl-piperidine derivatives as substance P receptor antagonists
|
|
GB9216911D0
(en)
*
|
1992-08-10 |
1992-09-23 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
ES2164072T3
(es)
*
|
1992-08-19 |
2002-02-16 |
Pfizer |
Heterociclos no aromaticos que contienen nitrogeno sustituidos con bencilamino.
|
|
US5387595A
(en)
*
|
1992-08-26 |
1995-02-07 |
Merck & Co., Inc. |
Alicyclic compounds as tachykinin receptor antagonists
|
|
US5344830A
(en)
*
|
1992-12-10 |
1994-09-06 |
Merck & Co., Inc. |
N,N-diacylpiperazine tachykinin antagonists
|
|
DK0675886T3
(da)
*
|
1992-12-10 |
2000-09-18 |
Pfizer |
Aminomethylensubstituerede ikke-aromatiske heterocykler og deres anvendelse som substance P-antagonister
|
|
US5830854A
(en)
*
|
1992-12-14 |
1998-11-03 |
Merck Sharp & Dohme, Limited |
Method of treating cystic fibrosis using a tachykinin receptor antagonist
|
|
US5340826A
(en)
*
|
1993-02-04 |
1994-08-23 |
Pfizer Inc. |
Pharmaceutical agents for treatment of urinary incontinence
|
|
US5393762A
(en)
*
|
1993-06-04 |
1995-02-28 |
Pfizer Inc. |
Pharmaceutical agents for treatment of emesis
|
|
US5854262A
(en)
*
|
1993-10-07 |
1998-12-29 |
Pfizer Inc. |
Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
|
|
US5610165A
(en)
*
|
1994-02-17 |
1997-03-11 |
Merck & Co., Inc. |
N-acylpiperidine tachykinin antagonists
|
|
IL112778A0
(en)
*
|
1994-03-04 |
1995-05-26 |
Merck & Co Inc |
Substituted heterocycles, their preparation and pharmaceutical compositions containing them
|
|
TW397825B
(en)
*
|
1994-10-14 |
2000-07-11 |
Novartis Ag |
Aroyl-piperidine derivatives
|
|
FR2725900B1
(fr)
*
|
1994-10-21 |
1997-07-18 |
Sanofi Sa |
Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
|
|
TW458774B
(en)
|
1995-10-20 |
2001-10-11 |
Pfizer |
Antiemetic pharmaceutical compositions
|
|
JP2000510870A
(ja)
*
|
1997-02-14 |
2000-08-22 |
バイエル・コーポレーシヨン |
Npy5受容体アンタゴニストとしてのアミド類
|
|
US6245817B1
(en)
|
1997-02-14 |
2001-06-12 |
Bayer Corporation |
NPY5 receptor antagonists and methods for using same
|
|
US6048900A
(en)
|
1998-02-13 |
2000-04-11 |
Bayer Corporation |
Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
|
|
EP0910565A1
(en)
*
|
1997-02-14 |
1999-04-28 |
Bayer Corporation |
Amide derivatives as selective neuropeptide y receptor antagonists
|
|
ES2304984T3
(es)
|
1999-11-03 |
2008-11-01 |
Amr Technology, Inc. |
Tetra-hidroisoquinolinas de sustitucion arilica y heteroarilica y su utilizacion para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
|
|
US7163949B1
(en)
|
1999-11-03 |
2007-01-16 |
Amr Technology, Inc. |
4-phenyl substituted tetrahydroisoquinolines and use thereof
|
|
ATE299875T1
(de)
*
|
2000-04-10 |
2005-08-15 |
Pfizer Prod Inc |
Benzoamid-piperidin verbindungen als substanz p- antagonisten
|
|
US7119207B2
(en)
|
2000-04-10 |
2006-10-10 |
Pfizer Inc |
Benzoamide piperidine containing compounds and related compounds
|
|
US7084152B2
(en)
|
2000-07-11 |
2006-08-01 |
Amr Technology, Inc. |
4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
|
|
CA2424292A1
(en)
*
|
2000-10-10 |
2002-04-18 |
Calyx Therapeutics, Inc. |
Tricyclic compounds and uses thereof
|
|
MX2007000428A
(es)
|
2004-07-15 |
2008-03-05 |
Amr Technology Inc |
Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina.
|
|
EP1888050B1
(en)
|
2005-05-17 |
2012-03-21 |
Merck Sharp & Dohme Ltd. |
cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
|
|
DE102005027168A1
(de)
*
|
2005-06-13 |
2006-12-14 |
Merck Patent Gmbh |
Tetrahydrochinoline
|
|
WO2007011820A2
(en)
|
2005-07-15 |
2007-01-25 |
Amr Technology, Inc. |
Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
|
WO2007041052A2
(en)
|
2005-09-29 |
2007-04-12 |
Merck & Co., Inc. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
GB0617867D0
(en)
*
|
2006-09-11 |
2006-10-18 |
Glaxo Group Ltd |
Chemical compounds
|
|
EP2698157B1
(en)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
SI2805945T1
(sl)
|
2007-01-10 |
2019-09-30 |
Msd Italia S.R.L. |
Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
|
|
JP2010516731A
(ja)
|
2007-01-24 |
2010-05-20 |
グラクソ グループ リミテッド |
2−メトキシ−5−(5−トリフルオロメチル−テトラゾール−1−イル)−ベンジル]−(2s−フェニル−ピペリジン−3s−イル)−アミンを含む医薬組成物
|
|
CA2682727C
(en)
|
2007-04-02 |
2016-03-22 |
Banyu Pharmaceutical Co., Ltd. |
Indoledione derivative
|
|
JP5501227B2
(ja)
|
2007-06-27 |
2014-05-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体
|
|
GB0716573D0
(en)
*
|
2007-08-24 |
2007-10-03 |
Glaxo Group Ltd |
Chemical compounds
|
|
CA2717509A1
(en)
|
2008-03-03 |
2009-09-11 |
Tiger Pharmatech |
Tyrosine kinase inhibitors
|
|
GB0804326D0
(en)
*
|
2008-03-07 |
2008-04-16 |
Glaxo Group Ltd |
Novel compounds
|
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
|
AR071997A1
(es)
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
|
|
UA105182C2
(ru)
|
2008-07-03 |
2014-04-25 |
Ньюрексон, Інк. |
Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
|
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
|
CN102638982B
(zh)
|
2009-05-12 |
2015-07-08 |
百时美施贵宝公司 |
(S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
|
|
MX2011011907A
(es)
|
2009-05-12 |
2012-01-20 |
Albany Molecular Res Inc |
7-([1,2,4,]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2, 3,4-tetrahidroisoquinolina y uso de la misma.
|
|
ES2446971T3
(es)
|
2009-05-12 |
2014-03-11 |
Albany Molecular Research, Inc. |
Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
|
|
EA023838B1
(ru)
|
2009-10-14 |
2016-07-29 |
Мерк Шарп Энд Домэ Корп. |
ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ
|
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
|
RU2745848C2
(ru)
|
2010-08-17 |
2021-04-01 |
Сирна Терапьютикс, Инк. |
ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
EP3358013B1
(en)
|
2012-05-02 |
2020-06-24 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
|
JP6280554B2
(ja)
|
2012-09-28 |
2018-02-14 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Erk阻害剤である新規化合物
|
|
JP6440625B2
(ja)
|
2012-11-14 |
2018-12-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
精神分裂病を処置するための方法および組成物
|
|
PT2925888T
(pt)
|
2012-11-28 |
2017-12-13 |
Merck Sharp & Dohme |
Composições e métodos para tratamento do cancro
|
|
EP2935263B1
(en)
|
2012-12-20 |
2018-12-05 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
CN104610146A
(zh)
*
|
2015-01-23 |
2015-05-13 |
常州大学 |
一种3-氮杂二环[5,1,0]-7-醛及合成方法
|
|
CN105330588B
(zh)
*
|
2015-10-16 |
2017-09-26 |
辽宁中医药大学 |
马齿苋中生物碱Oleracone及其提取分离方法
|
|
US10975084B2
(en)
|
2016-10-12 |
2021-04-13 |
Merck Sharp & Dohme Corp. |
KDM5 inhibitors
|
|
US11098059B2
(en)
|
2017-11-08 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
CA3108388A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
CN113121427B
(zh)
*
|
2021-03-19 |
2022-04-01 |
广东工业大学 |
一种喹啉类衍生物及其制备方法和应用
|